Medline vs Solventum
MDLN and SOLV side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MDLN and SOLV compare
Medline is the larger company, worth 3.1 times as much as Solventum ($42.2B against $13.8B).
Medline grew revenue faster over the last twelve months (11.5% versus −0.93% for Solventum).
Solventum keeps more of each dollar of sales as profit, with a net margin of 17.3% compared with 4.1% at Medline.
Solventum scores higher on the StockData Score (14 against 5 for Medline), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MDLN | SOLV |
|---|---|---|
| Size and price | ||
| Market cap | $42.2B | $13.8B |
| Share price | $32.12 | $81.33 |
| Change, 1 year | – | 16.6% |
| Beta (5Y) | – | 0.58 |
| Employees | 45K | 10K |
| StockData Score | ||
| Total score | 5 | 14 (better) |
| Valuation score | 0 | 6 (better) |
| Growth score | 2 | 2 |
| Performance score | 2 | 5 (better) |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 9.9× |
| P/S | 1.5× (better) | 1.7× |
| P/B | 3.6× | 2.9× (better) |
| EV/EBITDA | 18.5× | 7.2× (better) |
| P/FCF | 32.6× | – |
| PEG | – | 2.21 |
| FCF yield | 3.1% (better) | −0.85% |
| Fair value | $26.54 | $185.43 |
| Margin of safety | −21.0% | 56.1% (better) |
| Growth | ||
| Revenue growth (TTM) | 11.5% (better) | −0.93% |
| Net income growth (TTM) | – | 277% |
| EPS growth (TTM) | – | 277% |
| Profitability | ||
| Gross margin | 26.4% | 54.7% (better) |
| Operating margin | 7.8% | 25.0% (better) |
| Net margin | 4.1% | 17.3% (better) |
| FCF margin | 4.6% (better) | −1.4% |
| Return on equity | 10.0% | 34.0% (better) |
| Return on invested capital | 9.6% | 17.2% (better) |
| Financial health | ||
| Debt / equity | 1.09 | 1.06 (better) |
| Net debt / EBITDA | 3.07 | 1.81 (better) |
| Interest coverage | 2.3× | – |
| Current ratio | 4.33 (better) | 1.02 |
| Altman Z-score | 2.44 (better) | 2.14 |
| Piotroski F-score | – | 5 |
| Dividends and buybacks | ||
| Buyback yield | 0.08% | – |
| Shareholder yield | 0.08% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 57.1% | 75.0% |
| Held by insiders | 85.0% | 30.3% |
| Insider net buying, 12 months | −$13.4B | $100K (better) |
| Superinvestors holding | 4 (better) | 2 |
| Short interest, % of float | 26.7% | 4.1% |
Go deeper
- MDLN stock overview
- MDLN income statement
- MDLN valuation and score
- SOLV stock overview
- SOLV income statement
- SOLV valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.